iBio Inc. Annual report pursuant to Section 13 and 15(d)

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2018

The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):

The following table summarizes all stock option activity during the years ended June 30, 2018 and 2017:

	Stock ‎ Options			Weighted- ‎ average ‎ Exercise ‎ Price		Weighted- ‎ average ‎ Remaining ‎ Contractual ‎ Term (in years)		Aggregate ‎ Intrinsic Value ‎ (in thousands)
Outstanding as of July 1, 2016		1,227,333		$	13.10		6.4	$	993
Granted		158,500		$	4.00
Forfeited/expired		(31,000	)	$	11.11
Outstanding as of June 30, 2017		1,354,833		$	12.08		5.9	$	138
Granted		21,000		$	3.12
Forfeited/expired		(11,250	)	$	4.00
Outstanding as of June 30, 2018		1,364,583		$	12.01		4.9	$	-
As of June 30, 2018 vested and expected to vest		1,362,221		$	12.01		4.9	$	-

Exercisable as of June 30, 2018		1,144,754		$	12.59		4.3	$	-

The following table summarizes information about options outstanding and exercisable at June 30, 2018:

	Options Outstanding and Exercisable
	Number ‎ Outstanding		Weighted- ‎A verage ‎ Remaining Life ‎ In Years		Weighted- ‎A verage ‎ Exercise ‎ Price		Number ‎ Exercisable
Exercise prices:
$1.70 - $3.01		73,000		1.3	$	2.01		68,000
$3.10 - $4.90		271,250		7.4		4.04		157,753
$5.00 - $7.70		206,333		3.9		5.84		187,667
$8.40 - $13.80		272,000		4.6		10.47		272,000
$14.00 - $22.50		428,000		5.3		17.86		345,334
$26.90 - $30.70		114,000		2.6		30.30		114,000
		1,364,583		4.9	$	12.01		1,144,754

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: